Appili Therapeutics Inc Market Cap ($464.29K)
Market Cap & Net Worth: Appili Therapeutics Inc (APLI)
Appili Therapeutics Inc market cap. Appili Therapeutics Inc (TO:APLI) has a market capitalization of $464.29K (CA$641.83K) as of October 31, 2026. Listed on the TO stock exchange, this Canada-based company holds position #31103 globally and #1645 in its home market, demonstrating a -66.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Appili Therapeutics Inc's stock price CA$0.01 by its total outstanding shares 128366120 (128.37 Million).
Appili Therapeutics Inc Market Cap History (2019–2026)
Appili Therapeutics Inc market cap history from 2019 to 2026. Data shows change from $69.64 Million to $464.29K (-50.21% CAGR). Check Appili Therapeutics Inc stock quote for real-time trading data and today's change.
Appili Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Appili Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see cash flow conversion of Appili Therapeutics Inc for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
23.11x
Appili Therapeutics Inc's market cap is 23.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $113.29 Million | $199.11K | -$5.42 Million | 568.98x | N/A |
| 2021 | $10.68 Million | $199.11K | -$14.33 Million | 53.63x | N/A |
| 2022 | $4.18 Million | $1.39 Million | -$25.12 Million | 3.00x | N/A |
| 2023 | $3.25 Million | $334.18K | -$9.24 Million | 9.73x | N/A |
| 2024 | $3.25 Million | $827.41K | -$3.78 Million | 3.93x | N/A |
| 2025 | $2.32 Million | $100.44K | -$2.62 Million | 23.11x | N/A |
Competitor Companies of APLI by Market Capitalization
Companies near Appili Therapeutics Inc in the global market cap rankings as of October 31, 2026. See Appili Therapeutics Inc balance sheet quality to understand what proportion of total assets are financed by equity.
Key companies related to Appili Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Appili Therapeutics Inc (2019–2026)
Market capitalization of Appili Therapeutics Inc from 2019 to today. Between 2019 and today, Appili Therapeutics Inc's market cap moved from $69.64 Million to $ 464.29K, with a yearly change of -50.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$464.29K | -80.00% |
| 2025 | CA$2.32 Million | -28.57% |
| 2024 | CA$3.25 Million | 0.00% |
| 2023 | CA$3.25 Million | -22.22% |
| 2022 | CA$4.18 Million | -60.87% |
| 2021 | CA$10.68 Million | -90.57% |
| 2020 | CA$113.29 Million | +62.67% |
| 2019 | CA$69.64 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Appili Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $464.29K USD |
| MoneyControl | $464.29K USD |
| MarketWatch | $464.29K USD |
| marketcap.company | $464.29K USD |
| Reuters | $464.29K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Appili Therapeutics Inc
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paro… Read more